nodes	percent_of_prediction	percent_of_DWPC	metapath
Nepafenac—Diclofenac—Clonidine—glaucoma	0.387	1	CrCrCtD
Nepafenac—PTGS2—glaucoma	0.345	1	CbGaD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.000653	0.1	CbGpPWpGaD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.000519	0.0797	CbGpPWpGaD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.000446	0.0685	CbGpPWpGaD
Nepafenac—Endophthalmitis—Timolol—glaucoma	0.000421	0.00162	CcSEcCtD
Nepafenac—Dry eye—Apraclonidine—glaucoma	0.00042	0.00162	CcSEcCtD
Nepafenac—Lacrimation—Betaxolol—glaucoma	0.000417	0.00161	CcSEcCtD
Nepafenac—Photophobia—Bimatoprost—glaucoma	0.000414	0.0016	CcSEcCtD
Nepafenac—Eye irritation—Pilocarpine—glaucoma	0.000413	0.00159	CcSEcCtD
Nepafenac—Visual acuity reduced—Betaxolol—glaucoma	0.000412	0.00159	CcSEcCtD
Nepafenac—Cataract—Brimonidine—glaucoma	0.00041	0.00158	CcSEcCtD
Nepafenac—Dry eye—Bimatoprost—glaucoma	0.000408	0.00157	CcSEcCtD
Nepafenac—Lacrimation increased—Dorzolamide—glaucoma	0.000405	0.00156	CcSEcCtD
Nepafenac—Lacrimation increased—Travoprost—glaucoma	0.000403	0.00156	CcSEcCtD
Nepafenac—Ketorolac—PTGS2—glaucoma	0.0004	0.151	CrCbGaD
Nepafenac—Blepharitis—Betaxolol—glaucoma	0.000398	0.00154	CcSEcCtD
Nepafenac—Lacrimation increased—Brinzolamide—glaucoma	0.000398	0.00154	CcSEcCtD
Nepafenac—Cataract—Travoprost—glaucoma	0.00039	0.00151	CcSEcCtD
Nepafenac—Bromfenac—PTGS2—glaucoma	0.000384	0.145	CrCbGaD
Nepafenac—Lacrimation increased—Pilocarpine—glaucoma	0.000383	0.00148	CcSEcCtD
Nepafenac—Keratitis—Betaxolol—glaucoma	0.000378	0.00146	CcSEcCtD
Nepafenac—Blood pressure increased—Travoprost—glaucoma	0.000372	0.00143	CcSEcCtD
Nepafenac—Cataract—Pilocarpine—glaucoma	0.00037	0.00143	CcSEcCtD
Nepafenac—Blood pressure increased—Brinzolamide—glaucoma	0.000367	0.00142	CcSEcCtD
Nepafenac—Photophobia—Brimonidine—glaucoma	0.000367	0.00142	CcSEcCtD
Nepafenac—Eye pain—Apraclonidine—glaucoma	0.000366	0.00141	CcSEcCtD
Nepafenac—Dry eye—Brimonidine—glaucoma	0.000361	0.00139	CcSEcCtD
Nepafenac—Eye pain—Bimatoprost—glaucoma	0.000355	0.00137	CcSEcCtD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.000354	0.0544	CbGpPWpGaD
Nepafenac—Photophobia—Dorzolamide—glaucoma	0.00035	0.00135	CcSEcCtD
Nepafenac—Photophobia—Travoprost—glaucoma	0.000349	0.00135	CcSEcCtD
Nepafenac—Dry eye—Dorzolamide—glaucoma	0.000345	0.00133	CcSEcCtD
Nepafenac—Photophobia—Brinzolamide—glaucoma	0.000344	0.00133	CcSEcCtD
Nepafenac—Dry eye—Travoprost—glaucoma	0.000343	0.00132	CcSEcCtD
Nepafenac—Sinusitis—Carteolol—glaucoma	0.000341	0.00132	CcSEcCtD
Nepafenac—Lacrimation—Timolol—glaucoma	0.000341	0.00131	CcSEcCtD
Nepafenac—Dry eye—Brinzolamide—glaucoma	0.000339	0.00131	CcSEcCtD
Nepafenac—Visual acuity reduced—Timolol—glaucoma	0.000337	0.0013	CcSEcCtD
Nepafenac—Vomiting—Physostigmine—glaucoma	0.000333	0.00128	CcSEcCtD
Nepafenac—Arthritis—Bimatoprost—glaucoma	0.00033	0.00127	CcSEcCtD
Nepafenac—Hypersensitivity—Dipivefrin—glaucoma	0.000328	0.00127	CcSEcCtD
Nepafenac—Tiaprofenic acid—PTGS2—glaucoma	0.000326	0.123	CrCbGaD
Nepafenac—Diabetes mellitus—Brimonidine—glaucoma	0.000326	0.00126	CcSEcCtD
Nepafenac—Dry eye—Pilocarpine—glaucoma	0.000326	0.00126	CcSEcCtD
Nepafenac—Blepharitis—Timolol—glaucoma	0.000326	0.00126	CcSEcCtD
Nepafenac—Eye pain—Brimonidine—glaucoma	0.000314	0.00121	CcSEcCtD
Nepafenac—Nausea—Physostigmine—glaucoma	0.000311	0.0012	CcSEcCtD
Nepafenac—Keratitis—Timolol—glaucoma	0.000309	0.00119	CcSEcCtD
Nepafenac—Magnesium salicylate—PTGS2—glaucoma	0.000303	0.115	CrCbGaD
Nepafenac—Eye pain—Dorzolamide—glaucoma	0.0003	0.00116	CcSEcCtD
Nepafenac—Eye pain—Travoprost—glaucoma	0.000299	0.00115	CcSEcCtD
Nepafenac—Fenbufen—PTGS2—glaucoma	0.000297	0.112	CrCbGaD
Nepafenac—Eye pain—Brinzolamide—glaucoma	0.000295	0.00114	CcSEcCtD
Nepafenac—Arthritis—Brimonidine—glaucoma	0.000292	0.00113	CcSEcCtD
Nepafenac—Vision blurred—Metipranolol—glaucoma	0.000289	0.00112	CcSEcCtD
Nepafenac—Eye irritation—Betaxolol—glaucoma	0.000287	0.00111	CcSEcCtD
Nepafenac—Eye pain—Pilocarpine—glaucoma	0.000283	0.00109	CcSEcCtD
Nepafenac—Arthritis—Travoprost—glaucoma	0.000277	0.00107	CcSEcCtD
Nepafenac—Vision blurred—Carteolol—glaucoma	0.000268	0.00103	CcSEcCtD
Nepafenac—Lacrimation increased—Betaxolol—glaucoma	0.000266	0.00103	CcSEcCtD
Nepafenac—Hypertension—Metipranolol—glaucoma	0.000265	0.00102	CcSEcCtD
Nepafenac—Arthritis—Pilocarpine—glaucoma	0.000263	0.00102	CcSEcCtD
Nepafenac—Dry eye—Clonidine—glaucoma	0.00026	0.001	CcSEcCtD
Nepafenac—Salsalate—PTGS2—glaucoma	0.000258	0.0974	CrCbGaD
Nepafenac—Cataract—Betaxolol—glaucoma	0.000258	0.000994	CcSEcCtD
Nepafenac—Vision blurred—Latanoprost—glaucoma	0.000235	0.000905	CcSEcCtD
Nepafenac—Eye irritation—Timolol—glaucoma	0.000235	0.000905	CcSEcCtD
Nepafenac—Sinusitis—Bimatoprost—glaucoma	0.000232	0.000894	CcSEcCtD
Nepafenac—Photophobia—Betaxolol—glaucoma	0.00023	0.000888	CcSEcCtD
Nepafenac—Dry eye—Betaxolol—glaucoma	0.000226	0.000874	CcSEcCtD
Nepafenac—Lacrimation increased—Timolol—glaucoma	0.000217	0.000839	CcSEcCtD
Nepafenac—Eye disorder—Apraclonidine—glaucoma	0.000214	0.000824	CcSEcCtD
Nepafenac—Fenoprofen—PTGS2—glaucoma	0.000213	0.0805	CrCbGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Latanoprost—glaucoma	0.00021	0.000812	CcSEcCtD
Nepafenac—Cataract—Timolol—glaucoma	0.00021	0.000812	CcSEcCtD
Nepafenac—Angiopathy—Apraclonidine—glaucoma	0.000207	0.0008	CcSEcCtD
Nepafenac—Eye disorder—Bimatoprost—glaucoma	0.000207	0.000799	CcSEcCtD
Nepafenac—Sinusitis—Brimonidine—glaucoma	0.000205	0.000791	CcSEcCtD
Nepafenac—Diabetes mellitus—Betaxolol—glaucoma	0.000205	0.00079	CcSEcCtD
Nepafenac—Angiopathy—Bimatoprost—glaucoma	0.000201	0.000776	CcSEcCtD
Nepafenac—Blood pressure increased—Timolol—glaucoma	0.0002	0.000773	CcSEcCtD
Nepafenac—Nervous system disorder—Latanoprost—glaucoma	0.000199	0.000769	CcSEcCtD
Nepafenac—Mefenamic acid—PTGS2—glaucoma	0.000198	0.0747	CrCbGaD
Nepafenac—Skin disorder—Latanoprost—glaucoma	0.000197	0.000761	CcSEcCtD
Nepafenac—Eye pain—Betaxolol—glaucoma	0.000197	0.000761	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Diclofenamide—glaucoma	0.000197	0.000759	CcSEcCtD
Nepafenac—Sinusitis—Dorzolamide—glaucoma	0.000196	0.000756	CcSEcCtD
Nepafenac—Sinusitis—Travoprost—glaucoma	0.000195	0.000753	CcSEcCtD
Nepafenac—Sinusitis—Brinzolamide—glaucoma	0.000193	0.000743	CcSEcCtD
Nepafenac—Photophobia—Timolol—glaucoma	0.000188	0.000726	CcSEcCtD
Nepafenac—Vision blurred—Apraclonidine—glaucoma	0.000187	0.000724	CcSEcCtD
Nepafenac—Sinusitis—Pilocarpine—glaucoma	0.000185	0.000714	CcSEcCtD
Nepafenac—Dry eye—Timolol—glaucoma	0.000185	0.000714	CcSEcCtD
Nepafenac—Hypersensitivity—Metipranolol—glaucoma	0.000184	0.000711	CcSEcCtD
Nepafenac—Eye disorder—Brimonidine—glaucoma	0.000183	0.000708	CcSEcCtD
Nepafenac—Arthritis—Betaxolol—glaucoma	0.000183	0.000707	CcSEcCtD
Nepafenac—Vision blurred—Bimatoprost—glaucoma	0.000182	0.000702	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Methazolamide—glaucoma	0.000181	0.000699	CcSEcCtD
Nepafenac—Angiopathy—Brimonidine—glaucoma	0.000178	0.000687	CcSEcCtD
Nepafenac—Immune system disorder—Brimonidine—glaucoma	0.000177	0.000684	CcSEcCtD
Nepafenac—Eye disorder—Travoprost—glaucoma	0.000174	0.000673	CcSEcCtD
Nepafenac—Eye disorder—Brinzolamide—glaucoma	0.000172	0.000664	CcSEcCtD
Nepafenac—Hypersensitivity—Carteolol—glaucoma	0.000171	0.000659	CcSEcCtD
Nepafenac—Angiopathy—Travoprost—glaucoma	0.000169	0.000653	CcSEcCtD
Nepafenac—Immune system disorder—Travoprost—glaucoma	0.000169	0.00065	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Apraclonidine—glaucoma	0.000168	0.000649	CcSEcCtD
Nepafenac—Angiopathy—Brinzolamide—glaucoma	0.000167	0.000645	CcSEcCtD
Nepafenac—Hypertension—Bimatoprost—glaucoma	0.000167	0.000643	CcSEcCtD
Nepafenac—Immune system disorder—Brinzolamide—glaucoma	0.000166	0.000642	CcSEcCtD
Nepafenac—Dry mouth—Apraclonidine—glaucoma	0.000166	0.000639	CcSEcCtD
Nepafenac—Eye disorder—Pilocarpine—glaucoma	0.000165	0.000639	CcSEcCtD
Nepafenac—Dizziness—Metipranolol—glaucoma	0.000165	0.000639	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—FN1—glaucoma	0.000164	0.0252	CbGpPWpGaD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—glaucoma	0.000164	0.0251	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Bimatoprost—glaucoma	0.000163	0.000629	CcSEcCtD
Nepafenac—Hypersensitivity—Levobunolol—glaucoma	0.000161	0.000623	CcSEcCtD
Nepafenac—Pruritus—Diclofenamide—glaucoma	0.000161	0.000622	CcSEcCtD
Nepafenac—Eye pain—Timolol—glaucoma	0.000161	0.000621	CcSEcCtD
Nepafenac—Vision blurred—Brimonidine—glaucoma	0.000161	0.000621	CcSEcCtD
Nepafenac—Dry mouth—Bimatoprost—glaucoma	0.000161	0.00062	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—CA1—glaucoma	0.00016	0.0247	CbGpPWpGaD
Nepafenac—Nervous system disorder—Apraclonidine—glaucoma	0.000159	0.000615	CcSEcCtD
Nepafenac—Skin disorder—Apraclonidine—glaucoma	0.000158	0.000609	CcSEcCtD
Nepafenac—Headache—Metipranolol—glaucoma	0.000157	0.000605	CcSEcCtD
Nepafenac—Pruritus—Levobunolol—glaucoma	0.000155	0.000598	CcSEcCtD
Nepafenac—Nervous system disorder—Bimatoprost—glaucoma	0.000154	0.000596	CcSEcCtD
Nepafenac—Vision blurred—Dorzolamide—glaucoma	0.000154	0.000593	CcSEcCtD
Nepafenac—Dizziness—Carteolol—glaucoma	0.000153	0.000592	CcSEcCtD
Nepafenac—Vision blurred—Travoprost—glaucoma	0.000153	0.000591	CcSEcCtD
Nepafenac—Skin disorder—Bimatoprost—glaucoma	0.000153	0.00059	CcSEcCtD
Nepafenac—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—glaucoma	0.000152	0.0234	CbGpPWpGaD
Nepafenac—Vision blurred—Brinzolamide—glaucoma	0.000151	0.000583	CcSEcCtD
Nepafenac—Dizziness—Diclofenamide—glaucoma	0.000151	0.000582	CcSEcCtD
Nepafenac—Nausea—Metipranolol—glaucoma	0.000149	0.000574	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000148	0.0228	CbGpPWpGaD
Nepafenac—Hypertension—Brimonidine—glaucoma	0.000147	0.000569	CcSEcCtD
Nepafenac—Dizziness—Carbachol—glaucoma	0.000147	0.000568	CcSEcCtD
Nepafenac—Vision blurred—Pilocarpine—glaucoma	0.000145	0.000561	CcSEcCtD
Nepafenac—Headache—Carteolol—glaucoma	0.000145	0.00056	CcSEcCtD
Nepafenac—Vomiting—Diclofenamide—glaucoma	0.000145	0.000559	CcSEcCtD
Nepafenac—Dizziness—Levobunolol—glaucoma	0.000145	0.000559	CcSEcCtD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000145	0.0222	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Brimonidine—glaucoma	0.000144	0.000557	CcSEcCtD
Nepafenac—Pruritus—Latanoprost—glaucoma	0.000144	0.000555	CcSEcCtD
Nepafenac—Headache—Diclofenamide—glaucoma	0.000143	0.000551	CcSEcCtD
Nepafenac—Dry mouth—Brimonidine—glaucoma	0.000142	0.000549	CcSEcCtD
Nepafenac—Diclofenac—PTGS2—glaucoma	0.000142	0.0537	CrCbGaD
Nepafenac—Vomiting—Carbachol—glaucoma	0.000141	0.000546	CcSEcCtD
Nepafenac—Hypertension—Dorzolamide—glaucoma	0.000141	0.000544	CcSEcCtD
Nepafenac—Hypertension—Travoprost—glaucoma	0.00014	0.000541	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Apraclonidine—glaucoma	0.00014	0.000541	CcSEcCtD
Nepafenac—Headache—Carbachol—glaucoma	0.000139	0.000538	CcSEcCtD
Nepafenac—Hypertension—Brinzolamide—glaucoma	0.000138	0.000534	CcSEcCtD
Nepafenac—Nausea—Carteolol—glaucoma	0.000138	0.000531	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Travoprost—glaucoma	0.000137	0.00053	CcSEcCtD
Nepafenac—Headache—Levobunolol—glaucoma	0.000137	0.00053	CcSEcCtD
Nepafenac—Nervous system disorder—Brimonidine—glaucoma	0.000137	0.000528	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Bimatoprost—glaucoma	0.000136	0.000525	CcSEcCtD
Nepafenac—Dry mouth—Dorzolamide—glaucoma	0.000136	0.000524	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Brinzolamide—glaucoma	0.000136	0.000523	CcSEcCtD
Nepafenac—Skin disorder—Brimonidine—glaucoma	0.000135	0.000523	CcSEcCtD
Nepafenac—Nausea—Diclofenamide—glaucoma	0.000135	0.000522	CcSEcCtD
Nepafenac—Dry mouth—Travoprost—glaucoma	0.000135	0.000522	CcSEcCtD
Nepafenac—Dizziness—Latanoprost—glaucoma	0.000134	0.000518	CcSEcCtD
Nepafenac—Dry mouth—Brinzolamide—glaucoma	0.000134	0.000515	CcSEcCtD
Nepafenac—Vomiting—Methazolamide—glaucoma	0.000133	0.000515	CcSEcCtD
Nepafenac—Hypertension—Pilocarpine—glaucoma	0.000133	0.000514	CcSEcCtD
Nepafenac—Eye disorder—Clonidine—glaucoma	0.000132	0.00051	CcSEcCtD
Nepafenac—Nausea—Carbachol—glaucoma	0.000132	0.00051	CcSEcCtD
Nepafenac—Headache—Methazolamide—glaucoma	0.000131	0.000507	CcSEcCtD
Nepafenac—Nausea—Levobunolol—glaucoma	0.00013	0.000502	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—FN1—glaucoma	0.00013	0.02	CbGpPWpGaD
Nepafenac—Nervous system disorder—Travoprost—glaucoma	0.00013	0.000502	CcSEcCtD
Nepafenac—Skin disorder—Travoprost—glaucoma	0.000129	0.000497	CcSEcCtD
Nepafenac—Sinusitis—Betaxolol—glaucoma	0.000129	0.000497	CcSEcCtD
Nepafenac—Nervous system disorder—Brinzolamide—glaucoma	0.000128	0.000495	CcSEcCtD
Nepafenac—Angiopathy—Clonidine—glaucoma	0.000128	0.000495	CcSEcCtD
Nepafenac—Headache—Latanoprost—glaucoma	0.000127	0.000491	CcSEcCtD
Nepafenac—Skin disorder—Brinzolamide—glaucoma	0.000127	0.000491	CcSEcCtD
Nepafenac—Ketoprofen—PTGS2—glaucoma	0.000126	0.0475	CrCbGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—TXN—glaucoma	0.000125	0.0193	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000125	0.000484	CcSEcCtD
Nepafenac—Nausea—Methazolamide—glaucoma	0.000125	0.000481	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000122	0.0187	CbGpPWpGaD
Nepafenac—Gastrointestinal disorder—Brimonidine—glaucoma	0.00012	0.000464	CcSEcCtD
Nepafenac—Hypersensitivity—Apraclonidine—glaucoma	0.00012	0.000462	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—PTGS2—glaucoma	0.000119	0.0183	CbGpPWpGaD
Nepafenac—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000118	0.0181	CbGpPWpGaD
Nepafenac—Vision blurred—Clonidine—glaucoma	0.000116	0.000448	CcSEcCtD
Nepafenac—Eye disorder—Betaxolol—glaucoma	0.000115	0.000444	CcSEcCtD
Nepafenac—Pruritus—Apraclonidine—glaucoma	0.000115	0.000443	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Travoprost—glaucoma	0.000114	0.000442	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000113	0.000436	CcSEcCtD
Nepafenac—Angiopathy—Betaxolol—glaucoma	0.000112	0.000431	CcSEcCtD
Nepafenac—Pruritus—Bimatoprost—glaucoma	0.000111	0.00043	CcSEcCtD
Nepafenac—Immune system disorder—Betaxolol—glaucoma	0.000111	0.000429	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000109	0.000419	CcSEcCtD
Nepafenac—Dizziness—Apraclonidine—glaucoma	0.000107	0.000414	CcSEcCtD
Nepafenac—Sinusitis—Timolol—glaucoma	0.000105	0.000406	CcSEcCtD
Nepafenac—Dizziness—Bimatoprost—glaucoma	0.000104	0.000402	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000104	0.000402	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.000103	0.0159	CbGpPWpGaD
Nepafenac—Vomiting—Apraclonidine—glaucoma	0.000103	0.000398	CcSEcCtD
Nepafenac—Hypersensitivity—Brimonidine—glaucoma	0.000103	0.000396	CcSEcCtD
Nepafenac—Dry mouth—Clonidine—glaucoma	0.000102	0.000396	CcSEcCtD
Nepafenac—Headache—Apraclonidine—glaucoma	0.000102	0.000393	CcSEcCtD
Nepafenac—Vision blurred—Betaxolol—glaucoma	0.000101	0.00039	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—TXN—glaucoma	9.96e-05	0.0153	CbGpPWpGaD
Nepafenac—PTGS1—Eicosanoid Synthesis—PTGS2—glaucoma	9.88e-05	0.0152	CbGpPWpGaD
Nepafenac—Pruritus—Brimonidine—glaucoma	9.86e-05	0.000381	CcSEcCtD
Nepafenac—Headache—Bimatoprost—glaucoma	9.86e-05	0.000381	CcSEcCtD
Nepafenac—Nervous system disorder—Clonidine—glaucoma	9.85e-05	0.00038	CcSEcCtD
Nepafenac—Hypersensitivity—Dorzolamide—glaucoma	9.81e-05	0.000379	CcSEcCtD
Nepafenac—Hypersensitivity—Travoprost—glaucoma	9.77e-05	0.000377	CcSEcCtD
Nepafenac—Skin disorder—Clonidine—glaucoma	9.76e-05	0.000377	CcSEcCtD
Nepafenac—PTGS2—Arachidonic acid metabolism—CYP1B1—glaucoma	9.67e-05	0.0149	CbGpPWpGaD
Nepafenac—Nausea—Apraclonidine—glaucoma	9.64e-05	0.000372	CcSEcCtD
Nepafenac—Hypersensitivity—Brinzolamide—glaucoma	9.64e-05	0.000372	CcSEcCtD
Nepafenac—Dizziness—Acetazolamide—glaucoma	9.6e-05	0.000371	CcSEcCtD
Nepafenac—Pruritus—Dorzolamide—glaucoma	9.42e-05	0.000363	CcSEcCtD
Nepafenac—Eye disorder—Timolol—glaucoma	9.4e-05	0.000363	CcSEcCtD
Nepafenac—Pruritus—Travoprost—glaucoma	9.38e-05	0.000362	CcSEcCtD
Nepafenac—Nausea—Bimatoprost—glaucoma	9.35e-05	0.000361	CcSEcCtD
Nepafenac—Hypersensitivity—Pilocarpine—glaucoma	9.27e-05	0.000358	CcSEcCtD
Nepafenac—Pruritus—Brinzolamide—glaucoma	9.26e-05	0.000357	CcSEcCtD
Nepafenac—Vomiting—Acetazolamide—glaucoma	9.23e-05	0.000356	CcSEcCtD
Nepafenac—Dizziness—Brimonidine—glaucoma	9.22e-05	0.000356	CcSEcCtD
Nepafenac—Angiopathy—Timolol—glaucoma	9.12e-05	0.000352	CcSEcCtD
Nepafenac—Headache—Acetazolamide—glaucoma	9.1e-05	0.000351	CcSEcCtD
Nepafenac—Immune system disorder—Timolol—glaucoma	9.08e-05	0.000351	CcSEcCtD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	9.06e-05	0.00035	CcSEcCtD
Nepafenac—Dry mouth—Betaxolol—glaucoma	8.92e-05	0.000344	CcSEcCtD
Nepafenac—Pruritus—Pilocarpine—glaucoma	8.9e-05	0.000343	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—C1QB—glaucoma	8.83e-05	0.0136	CbGpPWpGaD
Nepafenac—Dizziness—Dorzolamide—glaucoma	8.8e-05	0.00034	CcSEcCtD
Nepafenac—Dizziness—Travoprost—glaucoma	8.76e-05	0.000338	CcSEcCtD
Nepafenac—Headache—Brimonidine—glaucoma	8.73e-05	0.000337	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Clonidine—glaucoma	8.67e-05	0.000335	CcSEcCtD
Nepafenac—Dizziness—Brinzolamide—glaucoma	8.65e-05	0.000334	CcSEcCtD
Nepafenac—Nausea—Acetazolamide—glaucoma	8.63e-05	0.000333	CcSEcCtD
Nepafenac—Nervous system disorder—Betaxolol—glaucoma	8.58e-05	0.000331	CcSEcCtD
Nepafenac—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	8.54e-05	0.0131	CbGpPWpGaD
Nepafenac—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	8.53e-05	0.0131	CbGpPWpGaD
Nepafenac—Skin disorder—Betaxolol—glaucoma	8.49e-05	0.000328	CcSEcCtD
Nepafenac—Vomiting—Dorzolamide—glaucoma	8.46e-05	0.000327	CcSEcCtD
Nepafenac—Headache—Dorzolamide—glaucoma	8.34e-05	0.000322	CcSEcCtD
Nepafenac—Vomiting—Brinzolamide—glaucoma	8.32e-05	0.000321	CcSEcCtD
Nepafenac—Dizziness—Pilocarpine—glaucoma	8.32e-05	0.000321	CcSEcCtD
Nepafenac—Headache—Travoprost—glaucoma	8.3e-05	0.00032	CcSEcCtD
Nepafenac—Nausea—Brimonidine—glaucoma	8.28e-05	0.00032	CcSEcCtD
Nepafenac—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	8.26e-05	0.0127	CbGpPWpGaD
Nepafenac—Vision blurred—Timolol—glaucoma	8.25e-05	0.000318	CcSEcCtD
Nepafenac—Headache—Brinzolamide—glaucoma	8.2e-05	0.000316	CcSEcCtD
Nepafenac—PTGS1—Overview of nanoparticle effects—TNF—glaucoma	8.04e-05	0.0124	CbGpPWpGaD
Nepafenac—Vomiting—Pilocarpine—glaucoma	8e-05	0.000309	CcSEcCtD
Nepafenac—Nausea—Dorzolamide—glaucoma	7.91e-05	0.000305	CcSEcCtD
Nepafenac—Headache—Pilocarpine—glaucoma	7.88e-05	0.000304	CcSEcCtD
Nepafenac—Nausea—Travoprost—glaucoma	7.87e-05	0.000304	CcSEcCtD
Nepafenac—Nausea—Brinzolamide—glaucoma	7.77e-05	0.0003	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—ABCA1—glaucoma	7.75e-05	0.0119	CbGpPWpGaD
Nepafenac—Hypertension—Timolol—glaucoma	7.56e-05	0.000292	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Betaxolol—glaucoma	7.55e-05	0.000291	CcSEcCtD
Nepafenac—Nausea—Pilocarpine—glaucoma	7.47e-05	0.000288	CcSEcCtD
Nepafenac—PTGS2—S1P1 pathway—VEGFA—glaucoma	7.44e-05	0.0114	CbGpPWpGaD
Nepafenac—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	7.4e-05	0.000286	CcSEcCtD
Nepafenac—Hypersensitivity—Clonidine—glaucoma	7.4e-05	0.000286	CcSEcCtD
Nepafenac—Dry mouth—Timolol—glaucoma	7.29e-05	0.000281	CcSEcCtD
Nepafenac—Pruritus—Clonidine—glaucoma	7.11e-05	0.000274	CcSEcCtD
Nepafenac—Nervous system disorder—Timolol—glaucoma	7.01e-05	0.00027	CcSEcCtD
Nepafenac—Skin disorder—Timolol—glaucoma	6.94e-05	0.000268	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—SOD1—glaucoma	6.91e-05	0.0106	CbGpPWpGaD
Nepafenac—Dizziness—Clonidine—glaucoma	6.64e-05	0.000256	CcSEcCtD
Nepafenac—Hypersensitivity—Betaxolol—glaucoma	6.44e-05	0.000249	CcSEcCtD
Nepafenac—Vomiting—Clonidine—glaucoma	6.39e-05	0.000247	CcSEcCtD
Nepafenac—PTGS2—Overview of nanoparticle effects—TNF—glaucoma	6.38e-05	0.00981	CbGpPWpGaD
Nepafenac—Headache—Clonidine—glaucoma	6.29e-05	0.000243	CcSEcCtD
Nepafenac—Pruritus—Betaxolol—glaucoma	6.19e-05	0.000239	CcSEcCtD
Nepafenac—Gastrointestinal disorder—Timolol—glaucoma	6.17e-05	0.000238	CcSEcCtD
Nepafenac—PTGS2—Selenium Micronutrient Network—ABCA1—glaucoma	6.15e-05	0.00946	CbGpPWpGaD
Nepafenac—Nausea—Clonidine—glaucoma	5.97e-05	0.00023	CcSEcCtD
Nepafenac—Dizziness—Betaxolol—glaucoma	5.78e-05	0.000223	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—GSTT1—glaucoma	5.69e-05	0.00875	CbGpPWpGaD
Nepafenac—Vomiting—Betaxolol—glaucoma	5.56e-05	0.000215	CcSEcCtD
Nepafenac—PTGS1—Arachidonic acid metabolism—PTGS2—glaucoma	5.49e-05	0.00844	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—SOD1—glaucoma	5.48e-05	0.00843	CbGpPWpGaD
Nepafenac—Headache—Betaxolol—glaucoma	5.48e-05	0.000211	CcSEcCtD
Nepafenac—PTGS1—Selenium Micronutrient Network—MTHFR—glaucoma	5.47e-05	0.00842	CbGpPWpGaD
Nepafenac—Hypersensitivity—Timolol—glaucoma	5.26e-05	0.000203	CcSEcCtD
Nepafenac—Nausea—Betaxolol—glaucoma	5.19e-05	0.0002	CcSEcCtD
Nepafenac—PTGS2—C-MYB transcription factor network—GSTM1—glaucoma	5.1e-05	0.00785	CbGpPWpGaD
Nepafenac—Pruritus—Timolol—glaucoma	5.05e-05	0.000195	CcSEcCtD
Nepafenac—Dizziness—Timolol—glaucoma	4.72e-05	0.000182	CcSEcCtD
Nepafenac—PTGS2—Spinal Cord Injury—NGFR—glaucoma	4.68e-05	0.0072	CbGpPWpGaD
Nepafenac—Vomiting—Timolol—glaucoma	4.54e-05	0.000175	CcSEcCtD
Nepafenac—PTGS1—Biological oxidations—CYP1B1—glaucoma	4.53e-05	0.00697	CbGpPWpGaD
Nepafenac—Headache—Timolol—glaucoma	4.48e-05	0.000173	CcSEcCtD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	4.41e-05	0.00678	CbGpPWpGaD
Nepafenac—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	4.39e-05	0.00674	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—MTHFR—glaucoma	4.35e-05	0.00668	CbGpPWpGaD
Nepafenac—Nausea—Timolol—glaucoma	4.24e-05	0.000164	CcSEcCtD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CTSA—glaucoma	4.23e-05	0.00651	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—BDNF—glaucoma	4.07e-05	0.00626	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	4.06e-05	0.00624	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NARFL—glaucoma	3.99e-05	0.00613	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA5A—glaucoma	3.99e-05	0.00613	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—IL1A—glaucoma	3.91e-05	0.00601	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	3.67e-05	0.00564	CbGpPWpGaD
Nepafenac—PTGS1—Biological oxidations—GSTM1—glaucoma	3.62e-05	0.00557	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—PTGS2—glaucoma	3.49e-05	0.00537	CbGpPWpGaD
Nepafenac—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	3.45e-05	0.0053	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	3.36e-05	0.00517	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA5A—glaucoma	3.17e-05	0.00487	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NARFL—glaucoma	3.17e-05	0.00487	CbGpPWpGaD
Nepafenac—PTGS2—Aryl Hydrocarbon Receptor—TNF—glaucoma	3.14e-05	0.00483	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN2A—glaucoma	3.08e-05	0.00473	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	3.03e-05	0.00465	CbGpPWpGaD
Nepafenac—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—glaucoma	2.94e-05	0.00452	CbGpPWpGaD
Nepafenac—PTGS2—Disease—LRP12—glaucoma	2.86e-05	0.0044	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	2.79e-05	0.00429	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	2.77e-05	0.00426	CbGpPWpGaD
Nepafenac—PTGS2—C-MYB transcription factor network—CDKN1B—glaucoma	2.73e-05	0.00419	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	2.37e-05	0.00365	CbGpPWpGaD
Nepafenac—PTGS1—Selenium Micronutrient Network—TNF—glaucoma	2.36e-05	0.00362	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—CDKN1B—glaucoma	2.08e-05	0.00319	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	2.03e-05	0.00312	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA1—glaucoma	1.95e-05	0.00299	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—MMP9—glaucoma	1.92e-05	0.00296	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CTSA—glaucoma	1.89e-05	0.0029	CbGpPWpGaD
Nepafenac—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	1.87e-05	0.00288	CbGpPWpGaD
Nepafenac—PTGS2—Disease—FGFR1OP—glaucoma	1.85e-05	0.00284	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HEYL—glaucoma	1.85e-05	0.00284	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CA2—glaucoma	1.78e-05	0.00274	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.74e-05	0.00268	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.74e-05	0.00268	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA1—glaucoma	1.55e-05	0.00238	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CTSA—glaucoma	1.5e-05	0.0023	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TNF—glaucoma	1.48e-05	0.00228	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CA2—glaucoma	1.41e-05	0.00217	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	1.41e-05	0.00217	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.38e-05	0.00212	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.38e-05	0.00212	CbGpPWpGaD
Nepafenac—PTGS2—Spinal Cord Injury—TP53—glaucoma	1.3e-05	0.00201	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—TXN—glaucoma	1.25e-05	0.00193	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.17e-05	0.00181	CbGpPWpGaD
Nepafenac—PTGS2—Disease—HDAC9—glaucoma	1.15e-05	0.00177	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.14e-05	0.00176	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.13e-05	0.00174	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.01e-05	0.00155	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—TXN—glaucoma	9.96e-06	0.00153	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTT1—glaucoma	9.73e-06	0.0015	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	9.09e-06	0.0014	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	9.01e-06	0.00138	CbGpPWpGaD
Nepafenac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	8.88e-06	0.00136	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	7.85e-06	0.00121	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CYP1B1—glaucoma	7.75e-06	0.00119	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—ABCA1—glaucoma	7.75e-06	0.00119	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTT1—glaucoma	7.72e-06	0.00119	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—GSTM1—glaucoma	6.2e-06	0.000953	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN2B—glaucoma	6.19e-06	0.000952	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—ABCA1—glaucoma	6.15e-06	0.000946	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CYP1B1—glaucoma	6.15e-06	0.000946	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—MTHFR—glaucoma	5.48e-06	0.000842	CbGpPWpGaD
Nepafenac—PTGS2—Disease—MTHFR—glaucoma	5.19e-06	0.000798	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—APOE—glaucoma	5.1e-06	0.000784	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—CAV1—glaucoma	5.05e-06	0.000777	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—GSTM1—glaucoma	4.92e-06	0.000756	CbGpPWpGaD
Nepafenac—PTGS2—Disease—APOE—glaucoma	4.83e-06	0.000743	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CAV1—glaucoma	4.79e-06	0.000736	CbGpPWpGaD
Nepafenac—PTGS2—Disease—BAD—glaucoma	4.5e-06	0.000692	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—MTHFR—glaucoma	4.35e-06	0.000668	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—APOE—glaucoma	4.05e-06	0.000622	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—CAV1—glaucoma	4.01e-06	0.000617	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—NOS3—glaucoma	3.82e-06	0.000587	CbGpPWpGaD
Nepafenac—PTGS2—Disease—NOS3—glaucoma	3.62e-06	0.000557	CbGpPWpGaD
Nepafenac—PTGS1—Metabolism—PTGS2—glaucoma	3.49e-06	0.000537	CbGpPWpGaD
Nepafenac—PTGS2—Disease—CDKN1B—glaucoma	3.14e-06	0.000482	CbGpPWpGaD
Nepafenac—PTGS2—Metabolism—NOS3—glaucoma	3.03e-06	0.000466	CbGpPWpGaD
